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OBJECTIVES We sought to define the vascular actions of the cardiac hormone brain natriuretic peptide
(BNP) on cellular proliferation and cyclic guanosine monophosphate (cGMP) in human
aortic vascular smooth muscle cells (HAVSMCs). Secondly, we investigated BNP and
acetylcholine (ACh) vasorelaxations in aortic rings from normal and atherosclerotic rabbits in
the presence and absence of long-term oral inhibition of neutral endopeptidase (NEP).
BACKGROUND The vascular actions of BNP are not well defined, despite the presence of its receptor in
vascular smooth muscle and the upregulation of NEP, the ectoenzyme that degrades BNP, in
the vascular wall in atherosclerosis.
METHODS HAVSMCs stimulated with fetal calf serum (FCS) were pulsed with bromodeoxyuridine
(BrdU) with and without BNP. The HAVSMCs were incubated in the presence and absence
of BNP to assess cGMP. Vasorelaxations to BNP and ACh were assessed in rings in normal
and atherosclerotic rabbits in the presence and absence of long-term oral inhibition of NEP,
together with assessment of atheroma formation.
RESULTS FCS-stimulated BrdU uptake in HAVSMCs was suppressed with BNP. BNP potentiated
cGMP in HAVSMCs. BNP resulted in potent vasorelaxation in normal isolated aortic rings,
which were impaired in atherosclerotic versus normal rabbits and preserved with NEP
inhibition, which also decreased atheroma formation. Relaxations to ACh, which were also
impaired in atherosclerosis, were preserved with inhibition of NEP.
CONCLUSIONS We conclude that BNP potently inhibits vascular smooth muscle cell proliferation and
potentiates the generation of cGMP. BNP potently relaxes the normal rabbit aorta, and this
response is impaired in atherosclerosis but preserved with inhibition of NEP, together with
a reduction in atheroma formation and preservation of relaxations to ACh. (J Am Coll
Cardiol 2000;35:796–801) © 2000 by the American College of Cardiology
Brain natriuretic peptide (BNP) is a member of a family of
structurally similar but genetically distinct peptides that
includes atrial and C-type natriuretic peptides (1–3). Brain
natriuretic peptide has been viewed as a volume-regulating
hormone of cardiac origin that mediates renal and endocrine
actions through activation of particulate guanylyl cyclase
(PGC) receptors and the generation of cyclic guanosine
monophosphate (cGMP) (4–6).
Although BNP functions as a circulating cardiac hor-
mone in the control of body fluid homeostasis (7), the
natriuretic peptide A receptor (NPR-A) that binds BNP is
also present in the vascular wall, underscoring a potential
role for BNP in the control of vascular function through
cGMP (8). Thus, BNP may function in parallel with nitric
oxide (NO), which is also a potent activator of cGMP
through activation of soluble guanylyl cyclase (9). The
biologic importance of BNP in vascular regulation is sup-
ported by recent studies that have reported that acute
natriuretic peptide receptor blockade in vivo increases cor-
onary vascular resistance (10), whereas genetic disruption of
the NPR-A receptor results in a model of hypertension, left
ventricular hypertrophy and sudden death (11). Studies have
also demonstrated that the biologic actions of the natriuretic
peptides are limited through rapid enzymatic degradation by
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the membrane-bound ectoenzyme neutral endopeptidase
(NEP), which has recently been shown to be increased in
the vascular wall in experimental atherosclerosis (12,13).
Indeed, long-term NEP inhibition has been reported to
decrease atheroma formation and preserve endothelium-
dependent vasorelaxations in association with a decrease in
serum cholesterol (13).
The current studies were designed to better define the
vascular biology of BNP and to confirm the role of chronic
NEP inhibition in modulating atheroma formation and
preserving endothelium-dependent vasorelaxations in ex-
perimental atherosclerosis. Specifically, we first determined
the ability of BNP to inhibit stimulated cell proliferation in
cultured human aortic vascular smooth muscle cells
(HAVSMCs) and to augment cGMP generation. Secondly,
we defined the ability of BNP to relax preconstricted
isolated aortic rings from normal rabbits in the presence and
absence of the endothelium. Thirdly, we determined
whether the vasorelaxing actions to BNP are impaired in
atherosclerosis and whether chronic NEP inhibition would
preserve vasorelaxations to BNP as well as endothelium-
dependent relaxations in association with a reduction in
atheroma formation.
We hypothesized that BNP would inhibit stimulated cell
proliferation and augment cGMP generation in
HAVSMCs. In addition, we hypothesized that BNP is a
potent endothelium-independent vasorelaxing factor in iso-
lated rabbit aortic rings and that this effect is attenuated in
a model of experimental atherosclerosis produced by hyper-
cholesterolemia but preserved by chronic oral inhibition of
NEP. Such restoration of BNP relaxations by NEP inhibi-
tion would be associated with a decrease in atheroma
formation and a preservation of endothelium-dependent
relaxations to acetylcholine (ACh), independent of de-
creases in serum cholesterol.
METHODS
Studies in cultured HAVSMCs. Cell proliferation studies
were performed according to previously described methods
(14). The HAVSMCs (passages 4 through 6) (Clonetics
Corporation Inc., San Diego, California) were grown to
confluence in culture media supplemented with required
growth factors, passaged in 96 well plates and incubated
with supplemented smooth muscle cell media for 24 h. The
supplemented medium was replaced with basal smooth
muscle cell media for 24 h to render the cells quiescent. The
cells were subsequently incubated in the presence or absence
of serum-supplemented media (5%), and in the presence of
serum-supplemented growth media along with exogenous
human BNP (1027 mol/liter) for 24 h. Proliferation was
assessed with bromodeoxyuridine (BrdU) uptake over the
next 24 h, as previously described (14).
Separate HAVSMCs (passages 4 through 6) were grown
to confluence in smooth muscle cell basal media supple-
mented with the required growth factors. The cells were
passaged to 24 well culture dishes and incubated in supple-
mented media and again grown to confluence over 48 h.
The supplemented medium was replaced with basal media
to render the cells quiescent for 24 h before incubation with
experimental conditions. The cells were then incubated in
the presence or absence of BNP (1027 mol/liter) and
3-isobutyl-1-methyl xanthine, a phosphodiesterase inhibi-
tor, for the indicated periods. Media were collected from the
wells, frozen and stored at 220°C until radioimmunoassay
was performed to measure cGMP levels by methods previ-
ously described (15).
Studies of vascular reactivity and atheroma formation.
Male New Zealand white rabbits were used in these studies.
The rabbits were housed individually in stainless-steel,
wire-bottomed cages in a room controlled with a 12-h
light–dark cycle. All experimental protocols were approved
by the Institutional Animal Care and Use Committee and
were performed in accordance with the recommendations of
the American Association for the Accreditation of Labora-
tory Animal Care.
Rabbits weighing 3.6 6 0.1 kg were assigned to three
groups: normal (n 5 8), cholesterol fed (n 5 7) and
cholesterol fed and treated with an orally active NEP
inhibitor, Candoxatril (UK 79300, Pfizer, United Kingdom)
(n 5 6). The normal group was fed a normal diet (150
g/day) for eight weeks. The cholesterol-fed group received a
1% cholesterol diet (150 g/day) for eight weeks to produce
atherosclerosis, as previously reported (16). The NEP inhi-
bition group received a 1% cholesterol diet (150 g/day) for
eight weeks and Candoxatril (20 mg/kg body weight per
day) dissolved in drinking water. After eight weeks the
animals were sacrificed with an overdose of intravenous
pentobarbital, and the aortas were excised and cleaned of
connective tissue on a towel soaked in cold Krebs solution.
The aortas were sectioned into 3- to 5-mm rings. Some
rings were denuded of endothelium by inserting a pair of
fine forceps into the lumen and gently rolling the ring back
and forth on Krebs-Ringer–wetted paper. Rings with and
without endothelium from individual rabbits were studied
in parallel.
After harvesting and cleaning the vessels, the aortic rings
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were suspended in organ chambers filled with aerated (95%
oxygen and 5% carbon dioxide) modified Krebs-Ringer
bicarbonate solution (composition in mmol/liter: 118.3
NaCl, 4.7 KCl, 2.5 CaCl2, 1.2 MgSO4, 25.0 NaHCO3,
0.026 calcium sodium EDTA and 11.1 dextrose-control
solution) at 37°C. During a 1- to 2-h equilibration period,
the maximal contractile response to KCl was determined at
previously determined optimal points in the length–tension
relation. The rings were then preconstricted with phenyl-
ephrine (1027.5 to 1028.5 mol/liter) until stable contraction
was attained. The rings were then exposed to cumulative
increases in concentration of ACh and BNP in half-log
increments (10211 to 1028.5 mol/liter).
In assessment of atheroma formation, the thoracic aortas
up to the origin of the second intercostal artery were used to
quantify plaque by oil-red O staining in rabbits fed a 1%
cholesterol diet for 10 weeks (n 5 6) and rabbits fed a 1%
cholesterol diet while receiving Candoxatril (20 mg/kg per
day) dissolved in drinking water (n 5 8). After immersion
fixation overnight in 10% neutral buffered Formalin, the
thoracic aorta was stained with oil-red O (0.3%). A single
longitudinal incision along the wall opposite the arterial
ostia was made, and the vessels were pinned open and
photographed. The percent plaque area was determined
from the values for the total area examined and the stained
area by threshold analysis using true-color image analyzer
software.
Statistical analysis. All data are expressed as the mean
value 6 SEM. Statistical evaluation of data was performed
using the Student t test for unpaired observations. When
more than two groups were compared, analysis of variance
with the Bonferroni correction was used. Values of p , 0.05
were considered significant. All statistical analysis was
performed on GraphPad Prism (version 2.0a) software.
RESULTS
Studies in cultured HAVSMCs. Figure 1A reports BNP-
mediated inhibition of fetal calf serum (FCS)-stimulated
replication in HAVSMCs as assessed by BrdU uptake. The
FCS increased BrdU uptake in HAVSMCs as compared
with cells incubated with smooth muscle cell basal media
(5% FCS 2.2 6 0.1 optical density units vs. smooth muscle
cell basal media 0.58 6 0.07; n 5 6, p , 0.05). Coincuba-
tion of exogenous BNP with FCS resulted in a decrease in
cell proliferation (FCS 2.2 6 0.1 vs. FCS 1 BNP 0.9 6
0.29; p , 0.05). Figure 1B reports cGMP generation and
BNP in HAVSMCs, demonstrating that BNP stimulated
cGMP accumulation at 3 h (1.13 6 0.19 pmol/ml vs.
undetectable; p , 0.05), 9 h (1.63 6 0.13 pmol/ml vs.
undetectable; p , 0.05) and 30 h (3.78 6 0.24 vs. 1.43 6
0.23 pmol/ml; p , 0.05).
Studies of vascular reactivity and atheroma formation.
Table 1 reports serum lipids and mean arterial pressure in
the normal, cholesterol-fed and cholesterol-fed plus NEP
inhibition groups. There was no difference between the
groups in mean arterial pressure. Total cholesterol, triglyc-
erides and low density lipoprotein cholesterol were markedly
elevated in the cholesterol-fed group in the absence of
changes in high density lipoprotein cholesterol. In the group
with long-term NEP inhibition, serum lipids were not
altered, as compared with the cholesterol-fed group.
Figure 2A reports dose-dependent vasorelaxations to
BNP with and without the endothelium. BNP induced
potent relaxations (100% maximal relaxation) in normal
isolated aortic rings preconstricted with phenylephrine.
Relaxations were unaffected by removal of the endothelium.
Figure 2B reports relaxations to BNP in normal, atheroscle-
rotic and atherosclerotic plus NEP inhibition groups, with
Figure 1. Left, Bar graph showing BrdU uptake in optical density
units as measured by colorimetry. *p , 0.05 vs. 0% FCS. †p ,
0.05 vs. 5% FCS. 0% FCS 5 BrdU uptake in cells not stimulated
with FCS; 5% FCS 5 BrdU uptake in cells stimulated with 5%
FCS; 5% FCS 1 BNP 5 BrdU uptake in cells coincubated in 5%
FCS and BNP (1027 mol/liter). Right, Bar graph showing cGMP
generation. *p , 0.05 vs. control. †p , 0.05 vs. 3 and 9 h. LOD 5
limit of detection.
Table 1. Hemodynamic Data and Serum Lipids
Measurements* Normal† Cholesterol‡ NEPI§
MAP (mm Hg) 86 6 2 80 6 1.88 82.5 6 1.6
Total cholesterol
(mg/dl)
39 6 3 1,725 6 119\ 1,720 6 427\
Total triglycerides
(mg/dl)
118 6 16 336 6 77\ 265 6 54\
HDL cholesterol
(mg/dl)
27 6 5 23 6 3 26 6 7
LDL cholesterol
(mg/dl)
3.60 6 1.17 1,579 6 126\ 1,514 6 367\
*Measurements were obtained before death, eight weeks after initiation of the diet.
†Normal indicates rabbits fed standard chow. ‡Cholesterol indicates rabbits fed a 1%
cholesterol diet. §NEPI indicates rabbits fed a 1% cholesterol diet and 20 mg/kg per
day of Candoxatril, an orally active NEP inhibitor. \p , 0.05 versus normal. Data are
presented as the mean value 6 SEM.
HDL 5 high density lipoprotein; LDL 5 low density lipoprotein; MAP 5 mean
arterial pressure; NEP 5 neutral endopeptidase; NEPI 5 neutral endopeptidase
inhibitor (Candoxatril).
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their associated effective concentration at 50% relaxation
(EC50). The BNP-induced relaxations were impaired in
atherosclerosis in association with a decrease in EC50.
Long-term NEP inhibition in cholesterol-fed rabbits pre-
served relaxations to BNP. Relaxations to ACh were also
impaired in atherosclerosis (EC50, 7.10 6 0.03* vs. 7.42 6
0.06, 2log mol/liter, *p , 0.05) and preserved with NEP
inhibition (EC50, 7.65 6 0.03, 2log mol/liter).
Figure 3 reports atherosclerotic plaque area as quantified
by oil-red O staining. Cholesterol-fed rabbits showed sig-
nificant atheroma formation in the thoracic aorta (48 6
5%), which was significantly (p , 0.05) decreased with
NEP inhibition (32 6 3%) in the absence of decreases in
serum cholesterol (Table 1).
DISCUSSION
The current studies were designed to address the vascular
biology of BNP. We report that BNP potently inhibits
proliferation in cultured HAVSMCs stimulated by FCS
and also significantly augments the generation of cGMP. In
addition, we report that BNP potently relaxes isolated rabbit
aortic rings independent of the endothelium, and that this
action is attenuated in experimental atherosclerosis. Impor-
tantly, these investigations also report that long-term oral
inhibition of NEP, the ectoenzyme that degrades the
natriuretic peptides, preserves relaxations to BNP in exper-
imental atherosclerosis in association with a reduction in
atheroma formation and preservation of endothelium-
dependent relaxations to ACh, independent of decreases in
elevated serum cholesterol.
Antiproliferative actions of BNP. Previous reports have
demonstrated that atrial and C-type natriuretic peptides
possess antimitogenic actions in vascular smooth muscle
cells through the NPR-A and NPR-B receptors, respec-
tively, which are both linked to particulate guanylate cyclase
and the generation of cGMP (17–21). To date, the effects of
BNP on vascular smooth muscle replication have been
incompletely defined. The importance of focusing on the
vascular biology of BNP is underscored by reports that BNP
may be the most biologically potent of the natriuretic
peptides with regard to its renal actions and its gene
activation in response to growth factors (22,23). We report,
for the first time to our knowledge, that BNP has antirep-
licative actions in cultured HAVSMCs. This observation
complements recent studies that have demonstrated that
Figure 2. Left, Relaxation curves to BNP in the presence (open circles) and absence (open triangles) of endothelium in preconstricted
aortic rings from normal rabbits. Right, Relaxation curves to BNP in the presence of endothelium in preconstricted aortic rings from
normal rabbits (open circles), atherosclerotic rabbits (open triangles) and atherosclerotic rabbits treated for eight weeks with the orally
active NEP inhibitor (NEPI), Candoxatril (UK 79300) (open diamonds). *p , 0.05 vs. normal. †p , 0.05 vs. atherosclerosis.
Figure 3. Bar graph showing atherosclerotic plaque area.
CHOL 5 cholesterol-fed untreated rabbits (n 5 6). NEPI 5
cholesterol-fed rabbits treated with Candoxatril (UK 79300) (n 5
8). *p , 0.05 vs. cholesterol.
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BNP inhibits oxidized low density lipoprotein–induced
migration of cultured HAVSMCs (24).
Cyclic cGMP actions of BNP. The current studies also
demonstrate, for the first time to our knowledge, that BNP
augments cGMP generation in HAVSMCs. Thus, BNP may
function as a vasoactive factor, similar to NO, which also
activates cGMP in vascular smooth muscle cells. Therefore,
BNP and NO represent a humoral pathway that has antipro-
liferative and vasorelaxing actions secondary to cGMP gener-
ation through activation of particulate and soluble guanylyl
cyclase, respectively (1). Further studies are needed to further
characterize the potential interactions between these two path-
ways, one of which is primarily related to circulating factors
(i.e., BNP) and the other which is primarily local (i.e., NO).
Vasorelaxing actions of BNP. Although vasorelaxations to
atrial and C-type natriuretic peptides have been well defined,
less is known about vasorelaxations to BNP (25). In addition,
although vasorelaxations to atrial and C-type natriuretic pep-
tides in experimental atherosclerosis have recently been re-
ported to be attenuated (13), the modulating effect of athero-
sclerosis on vasorelaxations to BNP has not been reported. The
current study therefore importantly extends previous investiga-
tions. First, we report that BNP potently and completely
relaxes the isolated rabbit aorta, and this action is not depen-
dent on the endothelium. Further, these vasorelaxing actions
are attenuated at low concentrations in the setting of experi-
mental atherosclerosis produced by hypercholesterolemia.
Thus, experimental atherosclerosis emerges as a disease state in
which the vasorelaxing actions of all the natriuretic peptides
(BNP and atrial and C-type natriuretic peptides) are impaired
in association with attenuation of the NO pathway—two
systems linked to cGMP.
Antiatherogenic actions of NEP inhibition. The ectoen-
zyme NEP is a widely distributed enzyme that rapidly degrades
the natriuretic peptides, thus limiting their biologic actions.
One report (13) documents that vascular wall NEP is increased
in the model of atherosclerosis we used in this study. Such
enhanced NEP activity could account in part for the reduced
vascular responsiveness to BNP, as well as to atrial and C-type
natriuretic peptides, as reported in this previous investigation
(13). Consistent with such an interpretation is the additional
report that inhibition of NEP preserves vasorelaxation to atrial
and C-type natriuretic peptides (13). We report in the current
study of atherosclerosis induced by a high cholesterol diet that
long-term oral inhibition of NEP preserves vasorelaxations to
BNP and attenuates atheroma formation in association with
preservation of endothelium-dependent relaxations to ACh.
The current investigation is in contrast to previous reports in
which the antiatherogenic effect of NEP inhibition occurred in
association with a decrease in serum cholesterol (13). As we
observed no decrease in serum cholesterol, the current obser-
vation suggests that the decrease in atheroma formation to
NEP inhibition is not due to cholesterol lowering. Our finding
that BNP has antimitogenic effects in cultured HAVSMCs
suggests that BNP could play a role in inhibiting vascular
smooth muscle cell proliferation in vivo. In addition, BNP
inhibits the migration of human coronary vascular smooth
muscle cells in vitro, and thus may play a role in preventing
migration in vivo (24). Consequently, augmentation of BNP
through NEP inhibition could account in part for the de-
creased atheroma formation we report in the current study. In
addition, augmentation of BNP through NEP inhibition may
also stimulate local release of C-type natriuretic peptide, as
reported by Nazario et al. (26), which could further inhibit
vascular smooth muscle cell replication and migration. The
antiatherogenic effect we report with long-term NEP inhibi-
tion is also not due to decreases in blood pressure, as there was
no difference in blood pressure between the cholesterol-fed and
the cholesterol-fed plus NEP inhibition groups.
Strategies for attenuating the pathogenesis of atherosclerosis
and its characteristic vascular wall dysfunction include inhibi-
tion of deleterious growth-promoting and vasoconstricting
factors as well as augmentation of antiproliferative and vasore-
laxing factors. Specifically, angiotensin-converting enzyme in-
hibition and L-arginine have been attractive experimental
therapeutic strategies that can be combined with lipid-lowering
agents (27–30). Such approaches have resulted in preservation
of endothelium-dependent vasorelaxations in the setting of
atherosclerosis through enhancement of endothelium-derived
NO production and other undefined mechanisms. Indeed, a
recent study reported the preservation of endothelium-
dependent relaxations to ACh in the setting of atherosclerosis
with long-term oral inhibition of NEP (13). To our knowl-
edge, our results are the first to confirm this important finding
and support the use of another pharmacologic agent, which
through cGMP secondary to activation of the natriuretic
peptides, preserves endothelium-dependent and -independent
function.
Conclusions. We report, for the first time to our knowl-
edge, that BNP has antireplicative effects on cultured
HAVSMCs in association with activation of cGMP gener-
ation. In addition, we report that vasorelaxations to BNP in
the normal rabbit aorta are endothelium independent and
impaired in experimental atherosclerosis. Finally, our results
demonstrate that long-term oral inhibition of NEP pre-
serves relaxations to BNP in atherosclerosis, while attenu-
ating atheroma formation and maintaining endothelial
function independent of reductions in serum cholesterol.
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